{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:33:53Z","timestamp":1792020833562,"version":"4.4.0"},"reference-count":68,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Meniere disease accounts for up to 15% of new vestibular diagnoses,; however, the optimal treatment has yet to be identified. A conservative treatment that would reduce or stop the vertigo episodes has not been identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the efficacy of a serotonin-norepinephrine reuptake inhibitor, venlafaxine, compared to placebo in treating patients with Meniere disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a randomized, double-blind, placebo-controlled, crossover pilot study spanning 22 weeks of follow-up. The clinical trial took place at a single-center tertiary referral center in Charleston, South Carolina. Participants were eligible if they were 18 years or older, had definite Meniere disease criteria as defined by Barany criteria, had at least 2 episodes in the last month, had not received intratympanic gentamycin, skull base surgery, or radiation therapy to the head or neck, not currently taking diuretics for Meniere disease, not currently taking oral steroids, and not currently taking serotonin-modulating medication. Patients were enrolled between February 2020 and September 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Patients received either 1 venlafaxine tablet, 37.5 mg, taken daily by mouth for 8 weeks or 1 placebo tablet taken daily by mouth for 8 weeks. Group 1 received placebo during phase 1 of the trial and venlafaxine in phase 2 of the trial. Group 2 received venlafaxine during phase 1 of the trial and placebo in phase 2 of the trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The main outcomes included the number of episodes and scores on the following scales: Dizziness Handicap Inventory, Neuropsychological Vertigo Inventory, Meniere Disease Patient-Oriented Symptom Index, 20-Item Short Form Health Survey, Penn State Worry Questionnaire, Cognitive Failure Questionnaire.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 182 patients were screened, and 40 participants with Meniere disease enrolled in the trial. The mean (SD) age of participants was 56.6 (14.3) years, and 22 (55%) were female. Participants had a mean (SD) of 13.8 (10.1) episodes per phase at baseline, 5.4 (4.4) episodes (\u03948.4) during the venlafaxine phase, and 5.0 (4.6) episodes (\u03948.8) during the placebo phase. No significant difference was identified between venlafaxine and placebo groups in the number of episodes or quality-of-life metrics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This randomized clinical trial failed to identify a difference between venlafaxine and placebo in number of episodes and other quality-of-life metrics. Future studies may benefit from different dosing regimens, larger cohorts, and longer lengths of therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04218123?locStr=Charleston,%20SC,%20USA&amp;amp;amp;country=United%20States&amp;amp;amp;state=South%20Carolina&amp;amp;amp;city=Charleston&amp;amp;amp;cond=Meniere%27s%20Disease&amp;amp;amp;rank=6\">NCT04218123<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoto.2024.2241","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:49:52Z","timestamp":1725551392000},"page":"935","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of a Serotonin-Norepinephrine Reuptake Inhibitor as a Treatment for Meniere Disease"],"prefix":"10.1001","volume":"150","author":[{"given":"Habib","family":"Rizk","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Monaghan","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Medical University of South Carolina, Charleston"},{"name":"College of Medicine, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Loma Linda University Health, Loma Linda, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Keith","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Medical University of South Carolina, Charleston"},{"name":"School of Osteopathic Medicine, Campbell University, Lillington, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, The State University of New York Upstate, Syracuse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun A.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"ooi240047r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/VES-150549","article-title":"Diagnostic criteria for Meni\u00e8re\u2019s disease.","volume":"25","author":"Lopez-Escamez","year":"2015","journal-title":"J Vestib Res"},{"issue":"5","key":"ooi240047r2","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.otc.2010.05.001","article-title":"Current epidemiology of Meniere\u2019s syndrome.","volume":"43","author":"Alexander","year":"2010","journal-title":"Otolaryngol Clin North Am"},{"issue":"1","key":"ooi240047r3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MAO.0000000000000596","article-title":"Vestibular migraine in an otolaryngology clinic: prevalence, associated symptoms, and prophylactic medication effectiveness.","volume":"36","author":"Van Ombergen","year":"2015","journal-title":"Otol Neurotol"},{"issue":"4","key":"ooi240047r4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaoto.2021.4282","article-title":"Pathogenesis and etiology of M\u00e9ni\u00e8re disease: a scoping review of a century of evidence.","volume":"148","author":"Rizk","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"11","key":"ooi240047r5","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1365-2826.2010.02060.x","article-title":"Expression and translocation of aquaporin-2 in the endolymphatic sac in patients with Meniere\u2019s disease.","volume":"22","author":"Maekawa","year":"2010","journal-title":"J Neuroendocrinol"},{"issue":"6","key":"ooi240047r6","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/MAO.0b013e3181b11db5","article-title":"Plasma vasopressin and V2 receptor in the endolymphatic sac in patients with delayed endolymphatic hydrops.","volume":"30","author":"Kitahara","year":"2009","journal-title":"Otol Neurotol"},{"issue":"12","key":"ooi240047r7","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/j.1365-2826.2008.01792.x","article-title":"Meniere\u2019s attacks occur in the inner ear with excessive vasopressin type-2 receptors.","volume":"20","author":"Kitahara","year":"2008","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"ooi240047r8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/msj.20041","article-title":"Anxiety disorders: a comprehensive review of pharmacotherapies.","volume":"75","author":"Hoffman","year":"2008","journal-title":"Mt Sinai J Med"},{"issue":"2","key":"ooi240047r9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2165\/00003495-199549020-00010","article-title":"Venlafaxine: a review of its pharmacology and therapeutic potential in depression.","volume":"49","author":"Holliday","year":"1995","journal-title":"Drugs"},{"issue":"2","key":"ooi240047r10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1526-4610.2005.05029.x","article-title":"The efficacy and safety of venlafaxine in the prophylaxis of migraine.","volume":"45","author":"Ozyalcin","year":"2005","journal-title":"Headache"},{"issue":"415","key":"ooi240047r11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1034\/j.1600-0447.106.s415.5.x","article-title":"Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors.","author":"Rudolph","year":"2002","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"6","key":"ooi240047r12","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00213-015-4187-4","article-title":"Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression.","volume":"233","author":"Poretti","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"ooi240047r13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/mlg.0b013e318031c802","article-title":"Expressions of aquaporin-2, vasopressin type 2 receptor, transient receptor potential channel vanilloid (TRPV)1, and TRPV4 in the human endolymphatic sac.","volume":"117","author":"Taguchi","year":"2007","journal-title":"Laryngoscope"},{"key":"ooi240047r14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3109\/00016489509121909","article-title":"Antidiuretic hormone (ADH) and endolymphatic hydrops.","volume":"519","author":"Takeda","year":"1995","journal-title":"Acta Otolaryngol Suppl"},{"key":"ooi240047r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000265113","article-title":"Hormonal aspects of M\u00e9ni\u00e8re\u2019s disease on the basis of clinical and experimental studies.","volume":"71","author":"Takeda","year":"2010","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"issue":"1-2","key":"ooi240047r16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-5955(99)00180-X","article-title":"Endolymphatic hydrops induced by chronic administration of vasopressin.","volume":"140","author":"Takeda","year":"2000","journal-title":"Hear Res"},{"issue":"2","key":"ooi240047r17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1006\/exnr.2001.7804","article-title":"Influence of serotonin on the glutamate-induced excitations of secondary vestibular neurons in the rat.","volume":"172","author":"Li Volsi","year":"2001","journal-title":"Exp Neurol"},{"issue":"4","key":"ooi240047r18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1460-9568.1995.tb00657.x","article-title":"Serotonin modulation of inferior olivary oscillations and synchronicity: a multiple-electrode study in the rat cerebellum.","volume":"7","author":"Sugihara","year":"1995","journal-title":"Eur J Neurosci"},{"issue":"1","key":"ooi240047r19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0006-8993(76)90335-8","article-title":"Characteristics and response differences to iontophoretically applied norepinephrine, D-amphetamine and acetylcholine on neurons in the medial and lateral vestibular nuclei of the cat.","volume":"112","author":"Kirsten","year":"1976","journal-title":"Brain Res"},{"issue":"10_Supplement","key":"ooi240047r20","article-title":"Lamotrigine as an effective pharmacotherapy for M\u00e9ni\u00e8re\u2019s disease: a case series (P2.277).","volume":"82","author":"Lixin","year":"2014","journal-title":"Neurol"},{"key":"ooi240047r21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/00004850-199503002-00004","article-title":"Safety and tolerance profile of venlafaxine.","volume":"10","author":"Danjou","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"ooi240047r22","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0149-2918(03)80210-2","article-title":"Venlafaxine: a 2003 update.","volume":"25","author":"Gutierrez","year":"2003","journal-title":"Clin Ther"},{"issue":"3","key":"ooi240047r23","doi-asserted-by":"publisher","first-page":"54S","DOI":"10.1097\/00004714-199606002-00011","article-title":"The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database.","volume":"16","author":"Rudolph","year":"1996","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"ooi240047r24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/2141-9248.126601","article-title":"The influence of psychological factors in Meniere\u2019s disease.","volume":"4","author":"Orji","year":"2014","journal-title":"Ann Med Health Sci Res"},{"issue":"10","key":"ooi240047r25","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1097\/00005537-200310000-00010","article-title":"Which comes first: psychogenic dizziness versus otogenic anxiety.","volume":"113","author":"Staab","year":"2003","journal-title":"Laryngoscope"},{"issue":"12","key":"ooi240047r26","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1080\/00016480701242469","article-title":"The relevance of migraine in patients with Meni\u00e8re\u2019s disease.","volume":"127","author":"Cha","year":"2007","journal-title":"Acta Otolaryngol"},{"issue":"11","key":"ooi240047r27","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1212\/01.WNL.0000036903.22461.39","article-title":"Migraine and M\u00e9ni\u00e8re\u2019s disease: is there a link.","volume":"59","author":"Radtke","year":"2002","journal-title":"Neurology"},{"issue":"1","key":"ooi240047r28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/lary.28546","article-title":"Treatment of vestibular migraine: a systematic review and meta-analysis.","volume":"131","author":"Byun","year":"2021","journal-title":"Laryngoscope"},{"issue":"9","key":"ooi240047r29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1017\/S0022215122001979","article-title":"A systematic review and meta-analysis of prophylactic medication of vestibular migraine.","volume":"137","author":"Yiannakis","year":"2023","journal-title":"J Laryngol Otol"},{"key":"ooi240047r30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fneur.2017.00524","article-title":"The efficacy of venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular migraine.","volume":"8","author":"Liu","year":"2017","journal-title":"Front Neurol"},{"issue":"1","key":"ooi240047r31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/lary.25445","article-title":"Propranolol and venlafaxine for vestibular migraine prophylaxis: a randomized controlled trial.","volume":"126","author":"Salviz","year":"2016","journal-title":"Laryngoscope"},{"key":"ooi240047r32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fneur.2015.00012","article-title":"New insights into pathophysiology of vestibular migraine.","volume":"6","author":"Espinosa-Sanchez","year":"2015","journal-title":"Front Neurol"},{"key":"ooi240047r33","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3182735","article-title":"The intimate relationship between vestibular migraine and Meniere disease: a review of pathogenesis and presentation.","volume":"2016","author":"Liu","year":"2016","journal-title":"Behav Neurol"},{"issue":"4","key":"ooi240047r34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/archotol.1990.01870040046011","article-title":"The development of the dizziness handicap inventory.","volume":"116","author":"Jacobson","year":"1990","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"3","key":"ooi240047r35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0194-5998(95)70102-8","article-title":"Equilibrium: Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere\u2019s disease.","volume":"113","year":"1995","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"12","key":"ooi240047r36","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1007\/s00405-016-4135-x","article-title":"The development of a new questionnaire for cognitive complaints in vertigo: the Neuropsychological Vertigo Inventory (NVI).","volume":"273","author":"Lacroix","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"ooi240047r37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.2044-8260.1982.tb01421.x","article-title":"The cognitive failures questionnaire (CFQ) and its correlates.","volume":"21","author":"Broadbent","year":"1982","journal-title":"Br J Clin Psychol"},{"issue":"9","key":"ooi240047r38","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"6","key":"ooi240047r39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0005-7967(90)90135-6","article-title":"Development and validation of the Penn State Worry Questionnaire.","volume":"28","author":"Meyer","year":"1990","journal-title":"Behav Res Ther"},{"issue":"10","key":"ooi240047r40","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archotol.131.10.863","article-title":"Validation of the Meniere\u2019s disease patient-oriented symptom-severity index.","volume":"131","author":"Gates","year":"2005","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"7","key":"ooi240047r41","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/00005650-198807000-00007","article-title":"The MOS short-form general health survey. Reliability and validity in a patient population.","volume":"26","author":"Stewart","year":"1988","journal-title":"Med Care"},{"issue":"1","key":"ooi240047r42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/AUD.0000000000001405","article-title":"Item level psychometrics of the dizziness handicap inventory in vestibular migraine and Meniere\u2019s disease.","volume":"45","author":"Rizk","year":"2024","journal-title":"Ear Hear"},{"issue":"7","key":"ooi240047r43","first-page":"463","article-title":"Approach to M\u00e9ni\u00e8re disease management.","volume":"65","author":"Wu","year":"2019","journal-title":"Can Fam Physician"},{"issue":"2","key":"ooi240047r44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015171.pub2","article-title":"Systemic pharmacological interventions for M\u00e9ni\u00e8re\u2019s disease.","volume":"2","author":"Webster","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"ooi240047r45","article-title":"Intratympanic corticosteroids for M\u00e9ni\u00e8re\u2019s disease.","volume":"2","author":"Webster","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"ooi240047r46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1055\/s-0037-1599276","article-title":"Endolymphatic sac surgery for M\u00e9ni\u00e8re\u2019s disease\u2014current opinion and literature review.","volume":"21","author":"Flores Garc\u00eda","year":"2017","journal-title":"Int Arch Otorhinolaryngol"},{"issue":"2_suppl","key":"ooi240047r47","first-page":"S1","article-title":"Clinical practice guideline: M\u00e9ni\u00e8re\u2019s disease.","volume":"162","author":"Basura","year":"2020","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"10","key":"ooi240047r48","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.4088\/JCP.10m06724","article-title":"Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.","volume":"72","author":"Zisook","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"ooi240047r49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11126-014-9334-2","article-title":"Venlafaxine versus applied relaxation for generalized anxiety disorder: a randomized controlled study on clinical and electrophysiological outcomes.","volume":"86","author":"Zullino","year":"2015","journal-title":"Psychiatr Q"},{"issue":"9","key":"ooi240047r50","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4088\/JCP.v58n0904","article-title":"Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression: the Venlafaxine XR 209 Study Group.","volume":"58","author":"Thase","year":"1997","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"ooi240047r51","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s11920-013-0384-1","article-title":"Depression in cognitive impairment.","volume":"15","author":"Pellegrino","year":"2013","journal-title":"Curr Psychiatry Rep"},{"key":"ooi240047r52","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2147\/NDT.S199746","article-title":"Cognitive impairment in depression: recent advances and novel treatments.","volume":"15","author":"Perini","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"ooi240047r53","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2023.104178","article-title":"Placebo effect in randomized controlled trials for Meniere\u2019s disease: a meta-analysis.","volume":"45","author":"Taniguchi","year":"2024","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"ooi240047r54","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MAO.0000000000002438","article-title":"Understanding the Dizziness Handicap Inventory (DHI): a cross sectional analysis of symptom factors that contribute to DHI variance.","volume":"41","author":"Formeister","year":"2020","journal-title":"Otol Neurotol"},{"issue":"3","key":"ooi240047r55","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4088\/JCP.v59n0305","article-title":"A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.","volume":"59","author":"Rudolph","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"ooi240047r56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11940-017-0476-z","article-title":"Current treatment options: vestibular migraine.","volume":"19","author":"Lauritsen","year":"2017","journal-title":"Curr Treat Options Neurol"},{"issue":"9","key":"ooi240047r57","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/01616412.2022.2056341","article-title":"Factors determining the response to treatment in patients with vestibular migraine.","volume":"44","author":"Kisabay Ak","year":"2022","journal-title":"Neurol Res"},{"issue":"2","key":"ooi240047r58","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3892\/etm.2013.1412","article-title":"Successful treatment of relapsed M\u00e9ni\u00e8re\u2019s disease using selective serotonin reuptake inhibitors: a report of three cases.","volume":"7","author":"Goto","year":"2014","journal-title":"Exp Ther Med"},{"issue":"1","key":"ooi240047r59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.21053\/ceo.2021.00920","article-title":"Cytokines and inflammation in Meniere disease.","volume":"15","author":"Frejo","year":"2022","journal-title":"Clin Exp Otorhinolaryngol"},{"issue":"1","key":"ooi240047r60","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1038\/s41598-018-23911-4","article-title":"Proinflammatory cytokines and response to molds in mononuclear cells of patients with Meniere disease.","volume":"8","author":"Frejo","year":"2018","journal-title":"Sci Rep"},{"key":"ooi240047r61","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.psyneuen.2017.03.015","article-title":"Reduced ENA78 levels as novel biomarker for major depressive disorder and venlafaxine efficiency: result from a prospective longitudinal study.","volume":"81","author":"Li","year":"2017","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"ooi240047r62","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ijcard.2008.02.013","article-title":"Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels.","volume":"134","author":"Tousoulis","year":"2009","journal-title":"Int J Cardiol"},{"issue":"7","key":"ooi240047r63","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1358\/dot.2019.55.7.3010575","article-title":"The neurobiology under the placebo effect.","volume":"55","author":"Girach","year":"2019","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"ooi240047r64","article-title":"Placebo interventions for all clinical conditions.","volume":"2010","author":"Hr\u00f3bjartsson","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"ooi240047r65","first-page":"735","article-title":"Placebo effects in treating migraine and other headaches.","volume":"11","author":"Diener","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"issue":"3","key":"ooi240047r66","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1586\/ern.10.8","article-title":"Migraine treatment and placebo effect.","volume":"10","author":"Speciali","year":"2010","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"ooi240047r67","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/070674371506000104","article-title":"The STAR*D Trial: it is time to reexamine the clinical beliefs that guide the treatment of major depression.","volume":"60","author":"Pigott","year":"2015","journal-title":"Can J Psychiatry"},{"issue":"1","key":"ooi240047r68","doi-asserted-by":"publisher","first-page":"105","DOI":"10.31887\/DCNS.2002.4.1\/ssonawalla","article-title":"Placebo response in depression.","volume":"4","author":"Sonawalla","year":"2002","journal-title":"Dialogues Clin Neurosci"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2822947\/jamaotolaryngology_rizk_2024_oi_240047_1731519051.11118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T16:01:26Z","timestamp":1731600086000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2822947"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2024.2241","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}